EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies

Ali Hussein Mer, Yousef Mirzaei, Fatemeh Misamogooe, Nader Bagheri, Ahmadreza Bazyari, Zahra Keshtkaran, Anna Meyfour, Alireza Shahedi, Zahra Amirkhani, Ameneh Jafari, Nesa Barpour, Saeed Jahandideh und 3 weitere

Drug Delivery and Translational Research · 2024-11 · 14 (11) · 2963-2988

DOI: 10.1007/s13346-024-01564-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 10.04.2024. Verfasst von Ali Hussein Mer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Mergasour Technical Institute, Erbil Polytechnic University, Erbil, Iraq. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 116 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cell-surface receptor tyrosine kinase c-mesenchymal-epithelial transition factor (c-Met) is overexpressed in a wide range of solid tumors, making it an appropriate target antigen for the development of anticancer therapeutics. Various antitumor c-Met-targeting therapies (including monoclonal antibodies [mAbs] and tyrosine kinases) have been developed for the treatment of c-Met-overexpressing tumors, most of which have so far failed to enter the clinic because of their efficacy and complications. Antibody-drug conjugates (ADCs), a new emerging class of cancer therapeutic agents that harness the target specificity of mAbs to deliver highly potent small molecules to the tumor with the minimal damage to normal cells, could be an attractive therapeutic approach to circumvent these limitations in patients with c-Met-overexpressing tumors. Of great note, there are currently nine c-Met-targeting ADCs being examined in different phases of clinical studies as well as eight preclinical studies for treating various solid tumors. The purpose of this study is to present a broad overview of clinical- and preclinical-stage c-Met-targeting ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metImmunoconjugatesNeoplasmsHumansAnimalsAntineoplastic Agents

Stichwörter der Autor:innen

ADCAntibody–drug conjugateImmunoconjugateTargeted therapyc-Metc-mesenchymal-epithelial transition factor

Substanzen

Proto-Oncogene Proteins c-metImmunoconjugatesAntineoplastic AgentsMET protein, human

Autor:innen und Institutionen

  • Department of Nursing, Mergasour Technical Institute, Erbil Polytechnic University, Erbil, Iraq.
  • Department of Medical Biochemical Analysis, Cihan University-Erbil, Erbil, Kurdistan Region, Iraq.
  • Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran.
  • Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, 8813733450, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Nursing, School of Nursing and Midwifery, Community Based Psychiatric Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Meghdad Abdollahpour-Alitappeh

Zitieren

APA

Mer, A. H., Mirzaei, Y., Misamogooe, F., Bagheri, N., Bazyari, A., Keshtkaran, Z., Meyfour, A., Shahedi, A., Amirkhani, Z., Jafari, A., Barpour, N., Jahandideh, S., Rezaei, B., Nikmanesh, Y., & Abdollahpour-Alitappeh, M. (2024). Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies. Drug Delivery and Translational Research, 14(11), 2963-2988. https://doi.org/10.1007/s13346-024-01564-3

Vancouver

Mer AH, Mirzaei Y, Misamogooe F, Bagheri N, Bazyari A, Keshtkaran Z, et al. Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies. Drug Delivery and Translational Research. 2024;14(11):2963-2988. doi:10.1007/s13346-024-01564-3

BibTeX
@article{Mer2024,
  author = {Mer, Ali Hussein and Mirzaei, Yousef and Misamogooe, Fatemeh and Bagheri, Nader and Bazyari, Ahmadreza and Keshtkaran, Zahra and Meyfour, Anna and Shahedi, Alireza and Amirkhani, Zahra and Jafari, Ameneh and Barpour, Nesa and Jahandideh, Saeed and Rezaei, Behzad and Nikmanesh, Yousef and Abdollahpour-Alitappeh, Meghdad},
  title = {Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  volume = {14},
  number = {11},
  pages = {2963--2988},
  doi = {10.1007/s13346-024-01564-3}
}
Kostenlos starten →